Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer.
Madan RA, Karzai F, Donahue RN, Al-Harthy M, Bilusic M, Rosner II, Singh H, Arlen PM, Theoret MR, Marté JL, Cordes L, Couvillon A, Hankin A, Williams M, Owens H, Lochrin SE, Chau CH, Steinberg S, Figg WD, Dahut W, Schlom J, Gulley JL.
Madan RA, et al. Among authors: figg wd.
J Immunother Cancer. 2021 Mar;9(3):e001556. doi: 10.1136/jitc-2020-001556.
J Immunother Cancer. 2021.
PMID: 33664086
Free PMC article.
Clinical Trial.